Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2
Abstract The outbreak of the novel coronavirus severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2), the causative agent of coronavirus disease 2019 (COVID‐19) respiratory disease, led to a global pandemic with high morbidity and mortality. Despite frenzied efforts in therapeutic development...
Saved in:
Main Authors: | Hualou Liang (Author), Liang Zhao (Author), Xiajing Gong (Author), Meng Hu (Author), Hongbin Wang (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro
by: Hua-Long Xiong, et al.
Published: (2021) -
Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
by: Tiziana Ginex, et al.
Published: (2021) -
In Silico Study for Similar FDA Approved Drugs as Inhibitors of SARS-CoV-2 Spike and the Host Receptor Proteins
by: Israa Mohamed Shamkh, et al.
Published: (2021) -
Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents
by: Mohammad Z. Ahmed, et al.
Published: (2021) -
Virtual screening and drug repositioning of FDA-approved drugs from the ZINC database to identify the potential hTERT inhibitors
by: Hasan Afzaal, et al.
Published: (2022)